Response Genetics announced this week that it has begun gene-expression screening studies for a Phase III trial of GlaxoSmithKline's investigational MAGE-A3 antigen-specific immunotherapeutic for non-small cell lung cancer.
GSK is studying the drug as an adjuvant therapy in MAGE-A3-positive patients with stage IB, II, or IIIA NSCLC. Approximately 35 percent to 50 percent of early NSCLC patients express the MAGE-A3 tumor-specific antigen.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.